NCT02236793已完成3 期
Phase III, Multicentre, Randomized, Parallel Group, Double Blinded and Control Group Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Adocia
- 入组人数
- 252
- 试验地点
- 32
- 主要终点
- Incidence of complete wound closure.
研究概览
简要总结
The present clinical trial is designed to assess the effectiveness of BioChaperone PDGF-BB applied at 4 µg/cm² every other day for up to 20 weeks and associated to Standard of Care as compared to Standard of Care alone for the treatment of neuropathic and neurovascular diabetic foot ulcers.(In order to ensure the double-blinding of the treatments, a sterile normal saline solution presented in the same multi-dose spray vials than BioChaperone PDGF-BB will be applied on patients of the control group).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women aged 18 years old or older, with type 1 or 2 diabetes mellitus
- •Patient with a single ulcer on the treated feet
- •Patient able and willing to provide informed consent
- •Patient able and willing to comply with protocol visits and procedure
- •Patient willing to use an off-loading method during the whole duration of the study
- •Full-thickness plantar, lateral or dorsal ulcer of the extremity (below the malleolus), excluding inter-digits ulcer (web spaces), extending through the epidermis and dermis, but not involving bone, tendons, ligaments or muscles (grade IA as defined by University of Texas Diabetic Wound Classification or Grade 1 according to Wagner classification)
- •Chronic ulcer of at least six weeks despite appropriate wound care
- •Ulcer area measured with the formula Length x Width x 0.8 following sharp debridement, of 1 to 10 cm², both inclusive
- •Well controlled infection or cellulitis (systemic antibiotherapy) before Baseline Visit
- •Peripheral neuropathy as assessed by Semmes- Weinstein monofilament test or by the bio esthesimeter (vibration perception threshold).
- •Ankle brachial pressure index > 0.60 and <1.3
- •Women surgically sterile, post-menopausal, or agree to practice adequate contraception and have a negative pregnancy test at screening. Non-nursing
排除标准
- •Inter digit ulcers
- •Ulcer of other cause or origin: electrical, chemical or radiation insult, bedsores, vascular ulcer or Charcot deformities ulcers
- •Charcot foot.
- •Wound originated from amputation bed
- •Active ulcer infection assessed by clinical examination and radiography if necessary. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement and controlled by standard wound care.
- •Active osteomyelitis affecting the area of the target ulcer
- •Poorly controlled diabetes (uncontrolled glycemia: HbA1c% >= 10%), renal failure (serum creatinine > 3.0 mg/dL), poor nutritional status (albumin < 3.0 g/dL or total protein < 6.5 g/dL)
- •Known connective tissue or malignant disease
- •Concomitant treatment with corticosteroids, immunosuppressive agents, radiation therapy, or anticancer chemotherapy
- •Use of investigational drug/device or growth factor within 30 days
- •Topical application of any advance wound care on this wound (antiseptics, antibiotics, debriders, enzyme) within 7 days
- •Vascular reconstruction within 8 weeks
- •Patients expected to be noncompliant with the protocol (not available for the duration of the trial, treatment or wound care compliance), or felt to be unsuitable by the Investigator for any other reason.
- •A history of severe cerebrovascular events
研究组 & 干预措施
BioChaperone PDGF-BB
Experimental
BioChaperone PDGF-BB administered every other day at the dose of 4µg/cm² for 20 weeks or until wound closure, associated with Standard of Care
干预措施: BioChaperone PDGF-BB (Drug)
Standard of Care
Placebo Comparator
Normal saline solution applied every other day at the same volume for up to 20 weeks, associated with standard wound care
干预措施: Standard of Care (Other)
结局指标
主要结局
Incidence of complete wound closure.
时间窗: 20 weeks
次要结局
- Time to achieve complete wound closure.(20 weeks)
- Percentage reduction in total ulcer surface area at each visit.(20 weeks)
- Incidence of complete wound healing(10 weeks)
- Number of ulcer recurrence observed 12 weeks after wound healing.(32 weeks)
- Treatment emergent adverse events.(52 weeks)
研究者
研究点 (32)
Loading locations...
相似试验
进行中（未招募）
3 期
Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)NCT05775848ML Bio Solutions, Inc.112
已完成
3 期
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) PatientsMultiple Sclerosis, Relapsing-RemittingNCT00099502Bayer2,244
已完成
3 期
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected AdultsHIV-1/HBV Co-InfectionNCT03547908Gilead Sciences244
已完成
3 期
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type PsoriasisPsoriasisNCT02905331Janssen Research & Development, LLC78
已完成
1 期
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA PropellantChronic Obstructive Pulmonary DiseaseNCT05477108AstraZeneca108